Biomoda, Inc. has allied with Quintiles Global Central Laboratories to help refine the automated image recognition system for measuring the photon emission rate and cell morphology of CyPath-stained cells to detect early stage lung cancer. Biomoda’s CyPath labeling solution for the early detection of cancers binds to cancer cells and fluoresces under specific frequencies of medium light. Biomoda is seeking FDA approval of its cytology-based screening technology as a Class III medical device. ...